Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions

Mise à jour : Il y a 4 ans
Référence : NCT00616681

Femme et Homme

  • | Pays :
  • Canada
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg dose administered under fasting conditions.


Critère d'inclusion

  • Seizures ,Epilepsy

Liens